Literature DB >> 7249146

The interaction of nogalamycin and analogs with DNA and other biopolymers.

W C Krueger, L M Pschigoda, S L Schpok, A Moscowitz, J P McGovren, P Neta, M V Merritt, L H Li.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7249146     DOI： 10.1016/0009-2797(81)90025-9

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN： 0009-2797            Impact factor:   5.192


× No keyword cloud information.
  8 in total

1.  Evaluation of menogaril in renal cell carcinoma. A Southwest Oncology Group phase II study (8504).

Authors:  R L Stephens; P Goodman; E D Crawford; C F Spicer; B A Lowe; F R Ahmann; R Chapman; R B Natale
Journal:  Invest New Drugs       Date:  1990       Impact factor: 3.850

2.  A phase II study of menogaril (NSC-269148) in colorectal carcinoma. A Southwest Oncology Group study.

Authors:  R P Whitehead; R H Earhart; T Fleming; P Goodman; J S Macdonald; T Pollock; J S Ungerleider
Journal:  Invest New Drugs       Date:  1990-08       Impact factor: 3.850

3.  Menogaril: a new anthracycline agent entering clinical trials.

Authors:  J P McGovren; K G Nelson; M Lassus; J C Cradock; J Plowman; J P Christopher
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

4.  Phase I clinical and pharmacokinetic study of menogaril (7-con-O-methylnogarol) in previously treated patients with acute leukemia.

Authors:  C Mazurek; J P Dutcher; E L Schwartz; S Garl; L Benson; P H Wiernik
Journal:  Invest New Drugs       Date:  1993-11       Impact factor: 3.850

5.  A phase I clinical and pharmacokinetic study of the oral and the oral/intravenous administration of menogaril.

Authors:  G R Weiss; T D Brown; J G Kuhn; D D Von Hoff; R H Earhart; W J Adams; J E Brewer; J D Hosley; D A Kasunic
Journal:  Invest New Drugs       Date:  1993-02       Impact factor: 3.850

6.  Phase II evaluation of menogaril (NSC-269148) in non-small cell lung carcinoma. A Southwest Oncology Group study.

Authors:  R B Vance; J J Crowley; J S Macdonald; F R Ahmann
Journal:  Invest New Drugs       Date:  1991-02       Impact factor: 3.850

7.  Menogaril, an anthracycline compound with a novel mechanism of action: cellular pharmacology.

Authors:  K Wierzba; Y Sugimoto; K Matsuo; T Toko; S Takeda; Y Yamada; S Tsukagoshi
Journal:  Jpn J Cancer Res       Date:  1990-08

8.  Menogaril, an anthracycline derivative, inhibits DNA topoisomerase II by stabilizing cleavable complexes.

Authors:  K Ono; Y Ikegami; M Nishizawa; T Andoh
Journal:  Jpn J Cancer Res       Date:  1992-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.